Tofacitinib
Tofacitinib is an oral inhibitor of janus kinases, which is approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis in adults; its efficacy in the treatment of psoriasis has also been demonstrated in clinical studies. A 10 mg daily dose has been observed to ac...
Saved in:
Main Author: | Nilgün Şentürk (Author) |
---|---|
Format: | Book |
Published: |
Galenos Publishing House,
2022-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tofacitinib: Revisión
by: Carlos Ríos Acosta, et al.
Published: (2016) -
SDRIFE Induced by Tofacitinib
by: Ramachandran Gnanasuriyan, et al.
Published: (2024) -
Tofacitinib in Hypertrophic Lichen Planus
by: Peter Seiringer, et al.
Published: (2020) -
Tofacitinib en artritis reumatoide
by: María del Carmen González, et al.
Published: (2017) -
Tofacitinib for the Treatment of Steroid-Induced Rosacea
by: Li T, et al.
Published: (2022)